The clinical value of immune checkpoint inhibitors in patients with advanced EGFR mutation-positive NSCLC remains a matter of debate because they may have less active against tumors with driver mutations and, when combined with TKIs, may increase toxicity, in particular pulmonary toxicity. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.